ATE382057T1 - Stabile formulierung von modifiziertem glp-1 - Google Patents

Stabile formulierung von modifiziertem glp-1

Info

Publication number: ATE382057T1
Authority: AT; Austria
Prior art keywords: stable formulation; modified glp; glp; modified; formulation
Prior art date: 2001-06-28

Application number

AT02745182T

Other languages

English (en)

Inventor

James Flink

Silke Larsen

Simon Jensen

Dorthe Engelund

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-28

Filing date

2002-06-27

Publication date

2008-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27545250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE382057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-27 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2008-01-15 Application granted granted Critical

2008-01-15 Publication of ATE382057T1 publication Critical patent/ATE382057T1/de

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Obesity (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

AT02745182T 2001-06-28 2002-06-27 Stabile formulierung von modifiziertem glp-1 ATE382057T1 (de)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DKPA200101010		2001-06-28
DKPA200101011		2001-06-28
DKPA200101052		2001-07-04
DKPA200101053		2001-07-04
DKPA200200092		2002-01-18
DKPA200200093		2002-01-18

Publications (1)

Publication Number	Publication Date
ATE382057T1 true ATE382057T1 (de)	2008-01-15

Family

ID=27545250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02745182T ATE382057T1 (de)	2001-06-28	2002-06-27	Stabile formulierung von modifiziertem glp-1

Country Status (10)

Country	Link
US (4)	US20030119734A1 (de)
EP (1)	EP1412384B1 (de)
JP (2)	JP5562510B2 (de)
AT (1)	ATE382057T1 (de)
AU (1)	AU2002316811A1 (de)
DE (1)	DE60224284T2 (de)
DK (1)	DK1412384T3 (de)
ES (1)	ES2298378T3 (de)
PT (1)	PT1412384E (de)
WO (1)	WO2003002136A2 (de)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
US20040037818A1 (en) *	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
US6926898B2 (en)	2000-04-12	2005-08-09	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2298378T3 (es)	2001-06-28	2008-05-16	Novo Nordisk A/S	Formulacion estable de glp-1 modificado.
CA2841097A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin and g-csf fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
US7635463B2 (en) *	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
AU2003219922B2 (en) *	2002-02-27	2009-09-10	Pharmain Corporation	Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) *	2004-04-23	2005-11-24	Bolotin Elijah M	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
JP5000848B2 (ja)	2002-05-21	2012-08-15	第一三共株式会社	グレリン含有医薬組成物
JP2005527224A (ja) *	2002-05-24	2005-09-15	ワラタファーマシューティカルズ，インコーポレイテッド	糖尿病の処置
CA2486584A1 (en)	2002-06-07	2003-12-18	Waratah Pharmaceuticals, Inc.	Compositions and methods for treating diabetes
MXPA05004202A (es) *	2002-10-22	2005-09-20	Waratah Pharmaceuticals Inc	Tratamiento de la diabetes.
BRPI0408978B8 (pt)	2003-04-08	2021-07-27	Novo Nordisk As	processos para regenerar uma fase estacionária cromatográfica
WO2004089985A1 (en) *	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
EP1633384B1 (de)	2003-05-15	2012-03-14	Trustees Of Tufts College	Stabile analoga von glp-1
AU2004243531B2 (en) *	2003-06-03	2009-11-05	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
EP1633391B1 (de)	2003-06-03	2011-10-19	Novo Nordisk A/S	Stabilisierte pharmazeutische peptid zusammensetzungen
KR101308912B1 (ko)	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
AU2004261353B2 (en)	2003-08-05	2009-12-10	Novo Nordisk A/S	Novel insulin derivatives
CN100535007C (zh) *	2003-08-21	2009-09-02	诺沃挪第克公司	胰高血糖素样肽的纯化
WO2005021022A2 (en) *	2003-09-01	2005-03-10	Novo Nordisk A/S	Stable formulations of peptides
US20060247167A1 (en) *	2003-09-01	2006-11-02	Novo Nordisk A/S	Stable formulations of peptides
WO2005023291A2 (en) *	2003-09-11	2005-03-17	Novo Nordisk A/S	Use of glp1-agonists in the treatment of patients with type i diabetes
RU2401276C2 (ru) *	2003-09-19	2010-10-10	Ново Нордиск А/С	Производные глюкагон-подобного пептида-1 (glp-1)
EP1670515A2 (de)	2003-09-19	2006-06-21	Novo Nordisk A/S	Albumin bindende derivate von therapeutischen peptiden
TW200522976A (en) *	2003-09-19	2005-07-16	Novo Nordisk As	Novel plasma protein affinity tags
KR101243648B1 (ko)	2003-11-20	2013-03-14	노보 노르디스크 에이/에스	제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
WO2005056036A2 (en)	2003-12-09	2005-06-23	Novo Nordisk A/S	Regulation of food preference using glp-1 agonists
JP2007514752A (ja) *	2003-12-16	2007-06-07	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	Ｇｌｐ−１医薬組成物
US20060210614A1 (en) *	2003-12-26	2006-09-21	Nastech Pharmaceutical Company Inc.	Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318837A1 (en) *	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060074025A1 (en) *	2003-12-26	2006-04-06	Nastech Pharmaceutical Company Inc.	Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20050143303A1 (en) *	2003-12-26	2005-06-30	Nastech Pharmaceutical Company Inc.	Intranasal administration of glucose-regulating peptides
BRPI0507189A (pt) *	2004-01-30	2007-06-26	Waratah Pharmaceuticals Inc	uso combinado de um agonista de glp-1 e compostos de gastrina
US8410047B2 (en)	2004-06-11	2013-04-02	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
BRPI0514408B8 (pt) *	2004-08-24	2021-05-25	Asubio Pharma Co Ltd	preparação liquida de peptídeo fisiologicamente ativo
JP4965446B2 (ja)	2004-08-31	2012-07-04	ノヴォノルディスクアー／エス	ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
JP5107713B2 (ja)	2004-10-07	2012-12-26	ノヴォノルディスクアー／エス	遅延性のエキセンディン−４化合物
JP2008515856A (ja) *	2004-10-07	2008-05-15	ノボノルディスクアクティーゼルスカブ	遅延性ｇｌｐ−１化合物
RU2413530C9 (ru) *	2004-11-12	2021-05-18	Ново Нордиск А/С	Стабильные препараты инсулинотропных пептидов
JP5185624B2 (ja)	2004-12-02	2013-04-17	ドマンティスリミテッド	血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
PL1845942T3 (pl)	2005-01-14	2014-07-31	Camurus Ab	Preparaty analogu GnRH
EP1843746B1 (de)	2005-01-14	2011-03-16	Camurus Ab	Somatostatin-analog-formulierungen
US9649382B2 (en)	2005-01-14	2017-05-16	Camurus Ab	Topical bioadhesive formulations
AU2005325510B2 (en)	2005-01-21	2009-07-02	Camurus Ab	Pharmaceutical lipid compositions
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
ES2484796T3 (es) *	2005-03-18	2014-08-12	Novo Nordisk A/S	Compuestos de GLP-1 extendidos
WO2006126673A1 (ja) *	2005-05-27	2006-11-30	Daiichi Sankyo Company, Limited	組み合わせによる糖尿病治療薬
US8097239B2 (en)	2005-06-06	2012-01-17	Camurus Ab	Controlled-release formulations
PL1888031T3 (pl)	2005-06-06	2013-04-30	Camurus Ab	Preparaty analogu glp-1
RS51319B (sr)	2005-09-22	2010-12-31	Biocompatibles Uk Limited	GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
WO2007067964A2 (en) *	2005-12-08	2007-06-14	Nastech Pharmaceutical Company Inc.	Mucosal delivery of stabilized formulations of exendin
KR101529318B1 (ko)	2005-12-19	2015-06-16	파마인 코포레이션	치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
EP1969004B1 (de)	2005-12-28	2011-08-10	Novo Nordisk A/S	Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
EP1854455B1 (de)	2006-05-10	2009-10-07	Biocompatibles UK Limited	GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
GB0711656D0 (en)	2007-06-15	2007-07-25	Camurus Ab	Formulations
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
GB0716385D0 (en)	2007-08-22	2007-10-03	Camurus Ab	Formulations
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2259802A1 (de)	2008-03-31	2010-12-15	Glaxo Group Limited	Arzneimittelfusionen und konjugate
WO2010015668A1 (en)	2008-08-06	2010-02-11	Novo Nordisk A/S	Conjugated proteins with prolonged in vivo efficacy
GB0815435D0 (en)	2008-08-22	2008-10-01	Camurus Ab	Formulations
EP2163243A1 (de) *	2008-09-12	2010-03-17	Biocompatibles UK Limited	Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
CN102202683A (zh)	2008-10-30	2011-09-28	诺沃-诺迪斯克有限公司	用少于每日一次的注射频率注射胰岛素来治疗糖尿病
CN102307897B (zh)	2008-12-05	2016-01-20	葛兰素集团有限公司	选出蛋白酶抗性多肽的方法
JP5816097B2 (ja)	2009-01-22	2015-11-18	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
US8779103B2 (en)	2009-03-27	2014-07-15	Glaxo Group Limited	Drug fusions and conjugates
WO2011015649A1 (en)	2009-08-06	2011-02-10	Novo Nordisk Health Care Ag	Growth hormones with prolonged in-vivo efficacy
KR20120092611A (ko)	2009-09-30	2012-08-21	글락소 그룹 리미티드	연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
RU2012134974A (ru)	2010-01-22	2014-02-27	Ново Нордиск Хелс Кеа Аг	Стабилизированное соединение гормона роста
PL2525834T3 (pl)	2010-01-22	2020-10-19	Novo Nordisk Health Care Ag	Hormony wzrostu o przedłużonej skuteczności in-vivo
US9168288B2 (en)	2010-04-09	2015-10-27	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
WO2012136790A1 (en)	2011-04-07	2012-10-11	Glaxo Group Limited	Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en)	2011-04-07	2012-10-11	Glaxo Group Limited	Cck compositions
WO2013083826A2 (en)	2011-12-09	2013-06-13	Novo Nordisk A/S	Glp-1 agonists
PE20150195A1 (es)	2012-05-25	2015-02-27	Camarus Ab	Formulaciones de agonistas del receptor de somatostatina
HUE049152T2 (hu)	2012-07-01	2020-09-28	Novo Nordisk As	Hosszantartó hatású GLP-1 peptidek alkalmazása
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CN103893744B (zh) *	2012-12-24	2017-12-19	杭州九源基因工程有限公司	一种治疗糖尿病的药物制剂及其制备方法
ES2841123T3 (es)	2013-04-05	2021-07-07	Formulacion Del Compuesto De La Hormona De Crecimiento	Formulación del compuesto de la hormona de crecimiento
EP2991672A1 (de)	2013-04-30	2016-03-09	Novo Nordisk A/S	Neuartiges verabreichungsschema
CN103405753B (zh) *	2013-08-13	2016-05-11	上海仁会生物制药股份有限公司	稳定的促胰岛素分泌肽水针药物组合物
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
JP6672175B2 (ja)	2014-05-07	2020-03-25	ノヴォノルディスクアー／エス	Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
WO2016038521A1 (en) *	2014-09-08	2016-03-17	Sun Pharmaceutical Industries Limited	Pharmaceutical compositions of liraglutide
CN104800572A (zh) *	2015-04-20	2015-07-29	陈兴田	一种治疗伴抑郁焦虑状态的功能性消化不良的中药制剂
EP3295952B1 (de) *	2015-05-13	2021-02-17	Hangzhou Jiuyuan Gene Engineering Co., Ltd	Pharmazeutische formulierung mit glp-1-analog und herstellungsverfahren dafür
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP2019506440A (ja) *	2016-03-01	2019-03-07	深▲せん▼翰宇薬業股▲ふん▼有限公司ＨｙｂｉｏＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	医薬組成物及びその製造方法
PL3448416T3 (pl) *	2016-04-28	2022-11-07	Novo Nordisk A/S	Semaglutyd w schorzeniach sercowo-naczyniowych
EP3515408A1 (de)	2016-09-23	2019-07-31	Delpor, Inc.	Stabile zusammensetzungen für inkretin-mimetische verbindungen
BR112020002804A2 (pt)	2017-08-24	2020-07-28	Novo Nordisk A/S	composição farmacêutica líquida, e, kit
CA3076664C (en)	2017-09-21	2023-10-10	EMULATE, Inc.	Physiology and pathophysiology of human gut: intestine-on-chip
CA3078652A1 (en)	2017-10-12	2019-04-18	Novo Nordisk A/S	Semaglutide in medical therapy
TWI705820B (zh)	2018-06-22	2020-10-01	美商美國禮來大藥廠	Gip/glp1促效劑組合物
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
MY206306A (en) *	2018-10-26	2024-12-07	Novo Nordisk As	Stable semaglutide compositions and uses thereof
EP3897570A1 (de)	2018-12-19	2021-10-27	KRKA, d.d., Novo mesto	Pharmazeutische zusammensetzung mit glp-1-analog
WO2020208541A1 (en)	2019-04-08	2020-10-15	Enzene Biosciences Limited	Composition comprising glp-1 analogue
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂
WO2021053578A1 (en) *	2019-09-19	2021-03-25	Dr. Reddy’S Laboratories Limited	Improved purification processes for liraglutide
GB201917723D0 (en)	2019-12-04	2020-01-15	Nv Rose Llc	Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
WO2021123228A1 (en)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
IL294521A (en) *	2020-02-18	2022-09-01	Novo Nordisk As	glp-1 compounds and their uses
CN115811970A (zh) *	2020-05-22	2023-03-17	韩美药品株式会社	胰高血糖素、glp-1和gip三重激动剂的长效缀合物的液体制剂
JP2024516395A (ja)	2021-04-27	2024-04-15	アードバーク・セラピューティクス・インコーポレイテッド	苦味受容体アゴニストおよび腸シグナル伝達化合物の組み合わせ
JP2024516834A (ja) *	2021-04-30	2024-04-17	イノベントバイオロジクス（スーチョウ）カンパニー，リミティド	Ｏｘｍ３保存剤、ｏｘｍ３製剤および調製方法
CN113249288B9 (zh) *	2021-07-13	2021-11-09	奥锐特药业(天津)有限公司	一种表达glp-1类似物的重组菌及其应用
US20260007869A1 (en)	2023-06-23	2026-01-08	Vaxess Technologies, Inc.	Microneedle array patches (maps), systems, and methods for manufacturing and using same

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4483849A (en) *	1983-01-07	1984-11-20	Carter William A	Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
US4468346A (en) *	1983-10-27	1984-08-28	The United States Of America As Represented By The Secretary Of Agriculture	Monoclonal antibodies to porcine immunoglobulins
DE3885459T2 (de) *	1987-05-14	1994-03-24	Commw Scient Ind Res Org	Molkeproteinfraktionen.
JPH03505401A (ja)	1988-06-27	1991-11-28	ジェネックス・コーポレーション	組換えタンパク質の培養培地への熱放出
EP0431679B1 (de)	1989-12-05	1994-10-19	Merck & Co. Inc.	Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe
DE4002066A1 (de)	1990-01-25	1991-08-01	Basf Ag	Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en) *	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv)	1991-05-07	1991-05-07	Tomas Moks	Peptide hormone solution
US5206219A (en) *	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
SG45449A1 (en)	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
US6284727B1 (en) *	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
WO1995005848A1 (en)	1993-08-24	1995-03-02	Novo Nordisk A/S	Protracted glp-1
GB9320782D0 (en)	1993-10-08	1993-12-01	Univ Leeds Innovations Ltd	Stabilising of proteins on solution
WO1995013825A1 (en)	1993-11-19	1995-05-26	G.D. Searle & Co.	TRANSDERMAL COMPOSITION OF N-[N-[5-[4-(AMINOIMINOMETHYL)PHENYL]-1-OXOPENTYL]-L-α-ASPARTYL]-L-PHENYLALANINE OR ITS ESTERS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
AU1847695A (en)	1994-02-22	1995-09-04	Syntex-Synergen Neuroscience Joint Venture, The	Pharmaceutical formulations of cntf
US5652216A (en) *	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
DK0699687T3 (da)	1994-08-31	2004-04-26	Mitsubishi Pharma Corp	Fremgangsmåde til oprensning af rekombinant humant serumalbumin
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69529998D1 (de) *	1994-12-23	2003-04-24	Novo Nordisk As	Glp-1 zusammensetzungen mit verlängerter wirkdauer
JP2000510813A (ja)	1995-02-06	2000-08-22	ジェネテイックス・インスティテュート・インコーポレイテッド	Ｉｌ−１２用処方
US5869602A (en) *	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
US5834428A (en) *	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
EP0828753B1 (de)	1995-06-02	2003-03-26	Novozymes A/S	BEHANDLUNG EINER PROTEINLÖSUNG MIT A1/Fe UND ANSCHLIESENDE MEMBRANKONZENTRATION
US5631347A (en)	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
BR9710130A (pt)	1996-07-03	1999-08-10	Alza Corp	Formulações de peptídeos próticas não-aquosas
JPH10101696A (ja)	1996-08-08	1998-04-21	Shinotesuto:Kk	形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
DE122009000079I2 (de) *	1996-08-30	2011-06-16	Novo Nordisk As Novo Alle	Glp-1 derivate
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
EP0998942A4 (de)	1997-01-20	2006-08-16	Japan Energy Corp	Verfahren zur stabilisierung von peptiden und gefriergetrochnete medizinische zusammensetzungen mit diesen
CA2236519C (en) *	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
AR012894A1 (es)	1997-06-13	2000-11-22	Lilly Co Eli	Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
WO1999016417A1 (en)	1997-10-01	1999-04-08	Flemington Pharmaceutical Corporation	Buccal, polar and non-polar spray or capsule
ES2195409T3 (es)	1997-10-24	2003-12-01	Genentech Inc	Purificacion de moleculas.
AU1617399A (en)	1997-12-05	1999-06-28	Eli Lilly And Company	Glp-1 formulations
DE29721752U1 (de)	1997-12-09	1998-02-12	Siemens AG, 80333 München	Crimpkontakt für Stecksysteme
US6380357B2 (en) *	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
DE69916811T2 (de) *	1998-02-27	2005-04-14	Novo Nordisk A/S	Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
AU3247799A (en) *	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1060191B1 (de) *	1998-02-27	2010-04-28	Novo Nordisk A/S	Abkömmlinge von glp-1 analogen
AU2610899A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	N-terminally modified glp-1 derivatives
DE69918070T2 (de) *	1998-03-13	2005-08-25	Novo Nordisk A/S	Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
AU3772199A (en) *	1998-05-01	1999-11-23	University Of Tennessee Research Corporation, The	Flow cytometric characterization of amyloid fibrils
WO2000015224A1 (en) *	1998-09-17	2000-03-23	Eli Lilly And Company	Protein formulations
CA2358107C (en)	1998-12-22	2011-08-23	Eli Lilly And Company	Shelf-stable formulation of glucagon-like peptide-1
RU2242244C2 (ru)	1999-01-14	2004-12-20	Амилин Фармасьютикалз, Инк.	Новые композиции агонистов эксендина и способы их введения
US6444788B1 (en) *	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
CA2361830A1 (en) *	1999-03-17	2000-09-21	Novo Nordisk A/S	Method for acylating peptides and novel acylating agents
EP1196189A2 (de)	1999-06-25	2002-04-17	Medtronic MiniMed, Inc.	Unterschiedliche wirkstoffe für diabetestherapie
EP1076066A1 (de)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
US7022674B2 (en) *	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
WO2001043762A2 (en)	1999-12-16	2001-06-21	Eli Lilly And Company	Polypeptide compositions with improved stability
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
AU2353701A (en)	2000-01-11	2001-07-24	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
US6734162B2 (en)	2000-01-24	2004-05-11	Minimed Inc.	Mixed buffer system for stabilizing polypeptide formulations
EP1396499A3 (de)	2000-01-27	2004-12-29	Eli Lilly And Company	Verfahren zur Lösung von Glucagon-ähnlichen Peptid-1 (GLP-1) Verbindungen
ATE264870T1 (de)	2000-01-27	2004-05-15	Lilly Co Eli	Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
US6569901B2 (en) *	2000-01-28	2003-05-27	Novo Nordisk A/S	Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en) *	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
AU2001248277A1 (en)	2000-04-06	2001-10-23	Novo-Nordisk A/S	Shock heat treatment of polypeptides
DE60137876D1 (de) *	2000-06-16	2009-04-16	Lilly Co Eli	Analoge des Glucagon-ähnlichen Peptids-1
JP4798833B2 (ja)	2000-10-24	2011-10-19	一般財団法人化学及血清療法研究所	加熱処理工程を含むヒト血清アルブミンの製造方法
AU2002228608A1 (en)	2000-12-13	2002-06-24	Eli Lilly And Company	Amidated glucagon-like peptide-1
AU2002239384B2 (en)	2000-12-13	2007-01-11	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
US20020151467A1 (en) *	2000-12-21	2002-10-17	Leung Frank K.	Methods and compositions for oral insulin delivery
GB2371227A (en)	2001-01-10	2002-07-24	Grandis Biotech Gmbh	Crystallisation - resistant aqueous growth hormone formulations
DK1360202T3 (da) *	2001-02-16	2008-09-22	Conjuchem Biotechnologies Inc	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
AU2002235731A1 (en)	2001-03-07	2002-09-19	Novo Nordisk A/S	Combined use of derivatives of glp-1 analogs and ppar ligands
US6573237B2 (en) *	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
EP1391209A4 (de)	2001-05-30	2009-12-16	Chugai Pharmaceutical Co Ltd	Proteinzubereitung
ES2298378T3 (es)	2001-06-28	2008-05-16	Novo Nordisk A/S	Formulacion estable de glp-1 modificado.
CN1335182A (zh)	2001-08-08	2002-02-13	华中科技大学	胰岛素口腔喷剂及其制备工艺
WO2003020201A2 (en)	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
EP1448222A4 (de)	2001-10-19	2006-05-17	Lilly Co Eli	Biphasische gemische von glp-1 und insulin
DE60307701T2 (de)	2002-03-15	2007-10-11	Natimmune A/S	Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
EP1494704A1 (de) *	2002-04-04	2005-01-12	Novo Nordisk A/S	Verwendung von glp-1-rezeptor-agonisten zur behandlung von kardiovascularen krankheiten
US7273921B2 (en) *	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
WO2004029076A2 (en)	2002-09-25	2004-04-08	Novo Nordisk A/S	Purification process comprising microfiltration at elevated temperatures
WO2004089985A1 (en) *	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
US8008255B2 (en)	2003-05-30	2011-08-30	Amylin Pharmaceuticals, Inc.	Methods and compositions for enhanced transmucosal delivery of peptides and proteins
AU2004243531B2 (en)	2003-06-03	2009-11-05	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
JP4800959B2 (ja)	2003-11-13	2011-10-26	ノヴォノルディスクアー／エス	糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
US20060287221A1 (en) *	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
KR101243648B1 (ko) *	2003-11-20	2013-03-14	노보 노르디스크 에이/에스	제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
EP1789075A4 (de)	2004-08-25	2009-07-01	Uab Research Foundation	Absorptionsverbesserer für die arzneimittelverabreichung
ES2575984T3 (es) *	2004-11-12	2016-07-04	Novo Nordisk A/S	Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
KR20090039787A (ko) *	2006-07-18	2009-04-22	센토코 인코포레이티드	인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
AR064623A1 (es) *	2006-12-21	2009-04-15	Centocor Inc	Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos

2002
- 2002-06-27 ES ES02745182T patent/ES2298378T3/es not_active Expired - Lifetime
- 2002-06-27 EP EP02745182A patent/EP1412384B1/de not_active Expired - Lifetime
- 2002-06-27 AU AU2002316811A patent/AU2002316811A1/en not_active Abandoned
- 2002-06-27 US US10/185,923 patent/US20030119734A1/en not_active Abandoned
- 2002-06-27 DE DE60224284T patent/DE60224284T2/de not_active Expired - Lifetime
- 2002-06-27 DK DK02745182T patent/DK1412384T3/da active
- 2002-06-27 AT AT02745182T patent/ATE382057T1/de active
- 2002-06-27 JP JP2003508375A patent/JP5562510B2/ja not_active Expired - Lifetime
- 2002-06-27 PT PT02745182T patent/PT1412384E/pt unknown
- 2002-06-27 WO PCT/DK2002/000437 patent/WO2003002136A2/en not_active Ceased
2007
- 2007-04-11 US US11/786,095 patent/US20080167226A1/en not_active Abandoned
2008
- 2008-12-24 US US12/343,722 patent/US20090111752A1/en not_active Abandoned
2010
- 2010-05-24 US US12/785,861 patent/US8846618B2/en not_active Expired - Lifetime
2011
- 2011-09-26 JP JP2011209396A patent/JP2012051894A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
PT1412384E (pt)	2008-03-28
JP5562510B2 (ja)	2014-07-30
WO2003002136A3 (en)	2004-03-04
US20090111752A1 (en)	2009-04-30
ES2298378T3 (es)	2008-05-16
DE60224284D1 (de)	2008-02-07
US20080167226A1 (en)	2008-07-10
AU2002316811A1 (en)	2003-03-03
US20100234299A1 (en)	2010-09-16
JP2004535442A (ja)	2004-11-25
EP1412384B1 (de)	2007-12-26
US8846618B2 (en)	2014-09-30
JP2012051894A (ja)	2012-03-15
US20030119734A1 (en)	2003-06-26
DE60224284T2 (de)	2008-12-18
DK1412384T3 (da)	2008-04-28
EP1412384A2 (de)	2004-04-28
WO2003002136A2 (en)	2003-01-09

Legal Events

Date

Code

Title

Description

2008-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1412384

Country of ref document: EP

Publication	Publication Date	Title
DE60224284D1 (de)	2008-02-07	Stabile formulierung von modifiziertem glp-1
CY1108532T1 (el)	2014-04-09	Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE60235083D1 (de)	2010-03-04	Substituierte tetracyclin-verbindungen zur behandlung von malaria
IS6520A (is)	2002-08-22	Ný efnasambönd
EE200300475A (et)	2004-02-16	Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
PA8575701A1 (es)	2004-02-07	Preparaciones acidas de insulina con estabilidad mejorada
ATE449079T1 (de)	2009-12-15	Pharmazeutische zusammensetzungen beinhaltend kristallsalze von 7-ä4-(4-fluorophenyl)-6- isopropyl-2-
EE04990B1 (et)	2008-04-15	HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
CY1106468T1 (el)	2012-01-25	Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
ATE376832T1 (de)	2007-11-15	Verzögert freisetzende formulierungen von oxymorphon
ATE486587T1 (de)	2010-11-15	Formulierungen zur oralen verabreichung von wirkstoffen
DK1172114T3 (da)	2005-01-24	Stabile koncentrerede insulinpræparater til pulmonær indgivelse
EE05385B1 (et)	2011-02-15	LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
DE60301339D1 (de)	2005-09-22	Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
DE60116359D1 (de)	2006-02-02	Kahalalid f formulierung
CY1105247T1 (el)	2010-03-03	Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
SE0102716D0 (sv)	2001-08-14	Novel compounds
NO20042563L (no)	2004-06-18	Preparatsammensetning som inneholder syreustabile fysiologisk aktive forbindelser og fremgangsmater til fremstilling derav
DE50115451D1 (de)	2010-06-02	Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
EE200300501A (et)	2003-12-15	Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
SE0003476D0 (sv)	2000-09-28	Compounds
DK1407780T3 (da)	2013-05-13	Farmaceutisk stabile hæmostatiske præparater
NO20054440L (no)	2005-09-26	Flytende formuleringer av tumornekrosefaktorbindende proteiner
ATE253359T1 (de)	2003-11-15	Antithrombotische mittel
DK1273301T3 (da)	2007-01-08	Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration